ReviewThe review of diabetic studies : RDS2012
Targeted antigen delivery to DEC-205⁺ dendritic cells for tolerogenic vaccination.
Review in The review of diabetic studies : RDS, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 41 citations in OpenAlex.
- Multiple sclerosis: molecular pathogenesis and therapeutic intervention.Signal transduction and targeted therapy · 2025Review
- Engineered Cancer Nanovaccines: A New Frontier in Cancer Therapy.Nano-micro letters · 2024Review
- The Application of Nanovaccines in Autoimmune Diseases.International journal of nanomedicine · 2024Review
- Selective ablation of thymic and peripheral Foxp3Frontiers in immunology · 2023Article
- Targeted delivery of autoantigen to dendritic cells prevents development of spontaneous uveitis.Frontiers in immunology · 2023Article
- Nanoparticles for vaccine and gene therapy: Overcoming the barriers to nucleic acid delivery.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology · 2022Review
- Cutting-Edge Delivery Systems and Adjuvants in Tolerogenic Vaccines: A Review.Pharmaceutics · 2022Review
- Transcriptional profiling of macrophages in situ in metastatic melanoma reveals localization-dependent phenotypes and function.Cell reports. Medicine · 2022Article
- Neuroprotective Potential of Dendritic Cells and Sirtuins in Multiple Sclerosis.International journal of molecular sciences · 2022Review
- Tolerogenic Immunotherapy: Targeting DC Surface Receptors to Induce Antigen-Specific Tolerance.Frontiers in immunology · 2021Review
- Recent Advances in Antigen-Specific Immunotherapies for the Treatment of Multiple Sclerosis.Brain sciences · 2020Review
- Targeting DEC-205Molecular medicine (Cambridge, Mass.) · 2018Article
- Glycan recognition by human blood mononuclear cells with an emphasis on dendritic cells.Glycoconjugate journal · 2018Article
- Bioconjugate Strategies for the Induction of Antigen-Specific Tolerance in Autoimmune Diseases.Bioconjugate chemistry · 2018Review
- New insight into type 1 diabetes development: resolving early diabetogenic CD4Annals of translational medicine · 2018Article
- Critical Role of TGF-β and IL-2 Receptor Signaling in Foxp3 Induction by an Inhibitor of DNA Methylation.Frontiers in immunology · 2018Article
- Targeting CLEC9A delivers antigen to human CD141JCI insight · 2016Article
- Advancing drug delivery systems for the treatment of multiple sclerosis.Immunologic research · 2015Review
- Regulatory dendritic cells for immunotherapy in immunologic diseases.Frontiers in immunology · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dendritic cells (DCs) and Foxp3-expressing CD4⁺ regulatory T (Treg) cells play non-redundant roles in the maintenance of peripheral tolerance to self-antigens, thereby preventing fatal autoimmunity. A common hallmark of intra- and extra-thymic Treg cell lineage commitment is the induction of Foxp3 expression as a consequence of appropriate T cell receptor engagement with MHC class II:agonist ligand. It has now become increasingly clear that agonist ligand presentation by immature DCs in the steady state induces T cell tolerance by both recessive and dominant mechanisms, rather than promoting productive T helper cell responses. In this context, the ability of steady-state DCs to promote the extrathymic conversion of initially naïve CD4⁺Foxp3⁻ T cells into Foxp3⁺ Treg cells is of particular interest as it provides novel perspectives to enhance antigen-specific Treg cell function in clinical settings of unwanted immunity, such as β-cell autoimmunity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.